- BySeeking Alpha-
By Christiana SciaudoneInvesting.com -- CureVac NV (NASDAQ:CVAC) tumbled almost 13% after Reuters reported the European Medicines Agency is unlikely to make a decision on its...
CureVac (CVAC) and collaboration partnerGlaxoSmithKline (GSK) announce thefirst preclinical data from second-generation COVID-19 vaccine candidate, CV2CoV in a rat model.CV2CoV is...
Traders await US economic data to justify strongest monthly stock advance in 3 decadesOil rebound slowsBitcoin close to all-time highKey EventsThe most powerful global, monthly...
As the world eagerly awaits results for the U.S. Presidential election, there's yet another highly anticipated event: a breakthrough in the coronavirus vaccine.Positive news about...
Amid the recent declines in broader markets, a blockbuster stock debut has been making headlines: cloud-based data-warehousing firm Snowflake (NYSE:SNOW).While the company priced...
CureVac AG is a Germany-based biotechnology company. The Company is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The Company's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.